key: cord-0705893-0wz63gh7
authors: Wong, Carlos K. H.; Au, Ivan C. H.; Cheng, Wing Yiu; Man, Kenneth K. C.; Lau, Kristy T. K.; Mak, Lung Yi; Lui, Sing Leung; Chung, Matthew S. H.; Xiong, Xi; Lau, Eric H. Y.; Cowling, Benjamin J.
title: Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: A self‐controlled case series study
date: 2022-03-22
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.16894
sha: ad8ec5efdbbbe20b5d29bc78c80f0379dec660d4
doc_id: 705893
cord_uid: 0wz63gh7

AIM: To investigate and quantify the risks of AKI and ALI associated with remdesivir use, given the underlying diseases of SARS‐CoV‐2 infection. METHODS: This self‐controlled case series (SCCS) study was conducted using electronic hospital records between 23 January 2020 and 31 January 2021 as retrieved from the Hong Kong Hospital Authority which manages all laboratory‐confirmed COVID‐19 cases in Hong Kong. Outcomes of AKI and ALI were defined using the KDIGO Guideline and Asia Pacific Association of Study of Liver consensus guidelines. Incidence rate ratios (IRR) for AKI and ALI following the administration of remdesivir (exposure) in comparison to a non‐exposure period were estimated using the conditional Poisson regression models. RESULTS: Of 860 COVID‐19 patients administered remdesivir during hospitalisation, 334 (38.8%) and 137 (15.9%) had incident ALI and AKI, respectively. Compared with the baseline period, both ALI and AKI risks were increased significantly during the pre‐exposure period (ALI: IRR = 6.169, 95% CI = 4.549–8.365; AKI: IRR = 7.074, 95% CI = 3.763–13.298) and remained elevated during remdesivir treatment. Compared to the pre‐exposure period, risks of ALI and AKI were not significantly higher in the first 2 days of remdesivir initiation (ALI: IRR = 1.261, 95% CI = 0.915–1.737; AKI: IRR = 1.261, 95% CI = 0.889–1.789) and between days 2 and 5 of remdesivir treatment (ALI: IRR = 1.087, 95% CI = 0.793–1.489; AKI: IRR = 1.152, 95% CI = 0.821–1.616). CONCLUSION: The increased risks of AKI and ALI associated with intravenous remdesivir treatment for COVID‐19 may be due to the underlying SARS‐CoV‐2 infection. The risks of AKI and ALI were elevated in the pre‐exposure period, yet no such increased risks were observed following remdesivir initiation when compared to the pre‐exposure period.

Coronavirus disease 2019 has posed an unprecedented challenge to nearly all governments worldwide, which are trying desperately to control the infection and mortality rate by means of vaccination and a variety of treatments. The pathogenesis of SARS-CoV-2 infection has been well-described. 1 Spike protein of coronaviruses binds with the receptor angiotensin-converting enzyme 2 (ACE2) expressed in alveolar cells, thereby promoting viral entry and utilising host cell machinery for replication with viral RNA-dependent RNA polymerase (RdRp). 2, 3 Meanwhile, podocytes and proximal tubular cells in the kidney also express high levels of ACE2, which smay contribute to the development of acute kidney injury (AKI) upon SARS-CoV-2 infection. 3 While a remarkable drop in kidney function indicates the onset of acute tubular injury, the situation is often mild. 4 Another possible injury mechanism involves the immune system that triggers inflammation and immune cell infiltration, which play a critical role in tubular injury and thrombi. 4 A similar mechanism mediated by immune response and thrombosis could also be responsible for hepatocytes injury. 5 Meanwhile, hepatic injury is also noticed alongside elevated levels of liver enzymes, such as aspartate transaminase (AST) and alanine transaminase (ALT). 6 In addition, ACE2 is expressed at the highest level in cholangiocytes, followed by hepatocytes based on RNA sequencing data. 7 Therefore, hepatotoxicity is directly linked to viral infection despite variation in expression level. 8 Remdesivir is an effective pharmaceutical option targeting the infection pathway and subsequent immune responses. It is a broadspectrum antiviral monophosphoramidate prodrug that is metabolised in the liver to form remdesivir triphosphate; the metabolite is a nucleotide analogue that competes with ATP and interferes with RdRp activity, so viral RNA replication ceases to operate. [9] [10] [11] In this regard, this drug could trigger mitochondrial injury as it inhibits mammalian DNA and RNA polymerases. 9, [11] [12] [13] [14] [15] This may lead to increased aminotransferase level in liver and mitochondrial injury in renal tubular cells, although action in the kidney may only occur with long-term treatment. 9, 12, 15 In addition, CYP3A4, which metabolises remdesivir in the liver, and hepatocytes transporters are susceptible to drug interactions with other agents, thus potentially causing liver damage. 11 Product label from FDA and EMA include increased transaminase level, bilirubin and creatinine as clinical implications, while the increase in liver enzymes is highlighted by FDA as a possible adverse side effect. 16, 17 Despite these possible injurious mechanisms, the previous usage of remdesivir treating MER and EVD demonstrates a safe profile without significant renal adverse events. 9, 18 Although cases of AKI and increased aminotransferase level have been reported for treating COVID-19, even among healthy volunteers, many randomised controlled studies have demonstrated limited adverse events with an acceptable safety profile. 9, [11] [12] [13] [14] [15] [19] [20] [21] In brief, kidney and liver injury are reported shortly after remdesivir initiation in case studies, 9, [22] [23] [24] but the exact injury mechanisms remain to be defined and investigated. Controlled trials may find remdesivir to be generally tolerable, [25] [26] [27] yet its safety data on AKI and acute liver injury (ALI) in the post-marketing real-world setting have not been published so far. With patients serving as their own control, this self-controlled case series (SCCS) study aims to estimate the risks of AKI and ALI with reference to remdesivir initiation among hospitalised COVID-19 patients who also had incident AKI or ALI.

We analysed all patients with COVID- 19 

Patients who had initiated remdesivir during their hospitalisation for COVID-19 were included in the current analysis if they had incident ALI or AKI. Remdesivir is one of the treatment options for patients hospitalised with COVID-19 in Hong Kong. 31 The recommended IRR = 1.261, 95% CI = 0.889-1.789) and between days 2 and 5 of remdesivir treatment (ALI: IRR = 1.087, 95% CI = 0.793-1.489; AKI: IRR = 1.152, 95% CI = 0.821-1.616).

The increased risks of AKI and ALI associated with intravenous remdesivir treatment for COVID-19 may be due to the underlying SARS-CoV-2 infection.

The risks of AKI and ALI were elevated in the pre-exposure period, yet no such increased risks were observed following remdesivir initiation when compared to the pre-exposure period. dosage is 200 mg once for the first day, and 100 mg once daily for the next 4 days or until hospital discharge. 32 Remdesivir is suggested to be used for COVID-19 patients with severe but non-critical disease (oxygen saturation <94% on room air); and against routine use in critical cases such as admission to an intensive care unit (ICU), requiring the initiation of high-flow nasal oxygen, mechanical ventilation or extracorporeal membrane oxygenation (ECMO). 31 ALI was defined as satisfying at least one of the following conditions 33 : (i) increase in ALT was over two times the upper limit of normal (ULN); (ii) increase in AST was over two times the ULN; (iii) increase in total bilirubin was over two times the ULN; or (iv) the international normalised ratio (INR) was over 1.7. According to the Asia Pacific Association of Study of Liver consensus guidelines, 34 Definition of ALI and AKI referred to serum abnormality at any point during the observation period.

The SCCS was used to investigate the association of remdesivir use for COVID-19 treatment and the risk of ALI or AKI. The SCCS study design relies on comparisons within individuals who have experienced both the outcome and exposure of interest, with participants serving as their own control. 36 Incidence rate ratios (IRRs) are derived by comparing the rate of events during periods of medication exposure with the rate during all other observed time periods (ie, without medication). The major advantage of SCCS lies in its ability to control for the fixed confounders and time-invariant confounding that possibly vary between individuals (namely socioeconomic factors, and genetic factors). 37

In SCCS, there were three key assumptions such that the study would provide valid and unbiased estimates. 37 First, recurrent events of ALI and AKI among remdesivir users were assumed to be independent. If the events were dependent, it would be possible for the first event to increase the risk of a future event, 37 so the only first incident event was studied. Second, the occurrence of an event must not alter the probability of subsequent exposure. Therefore, pre-exposure period was included to resolve the problem that the occurrence of ALI and AKI may temporarily alter the probability of remdesivir initiation.

Third, there must be no censoring by the outcome of interest. It is inadmissible for SCCS analyses to censor exposure by the outcome since the exposure history would then be event-dependent and violate another SCCS assumption. This would produce bias in an unpredictable direction. When a risk period is censored by patient's death, the incidence rate would be estimated to be higher. If death occurs during the baseline period, IRR would be biassed downwards.

On the other hand, death during the exposed period would bias IRR upwards. This is a case of event-dependent observation periods ( Figure S1 ), which violates the assumption of SCCS, and requires an extended version of SCCS which is adjusted for censoring by applying a weighting according to the duration from the event to the end of observation. 38

Study exposure was the initiation of remdesivir treatment in patients hospitalised with COVID-19. Patients were censored on the following dates: date of hospital discharge, death or the end of the observation period (30 April 2021), whichever occurred the earliest. The risk periods were patient time divided into six mutually exclusive risk windows: (i) the baseline period covered that from hospital admission to 3 days before treatment initiation, and more than 5 days after treatment to the end of the observation period, which would be used as reference for comparison; and the exposure-related risk periods were defined as (ii) pre-exposure period (1-2 days before treatment initiation), (iii) first 2 days (days 0-1) on remdesivir initiation, (iv) days 2-5 on treatment, (v) more than 5 days on drug use to the end of treatment (applicable to patients on an extended treatment course only), and (vi) wash-out period (within 5 days after treatment). The pre-exposure period, which was designed to evaluate any increased incidences of ALI or AKI before the initiation of remdesivir, would help prevent any temporary changes in probability of exposure. 37 Figure 1 illustrates the schema of SCCS and describes the six risk periods in this observational study.

F I G U R E 1 Study schema and definitions of treatment periods. The study was divided into six separate periods: Pre-exposure period, first 2 days on treatment, day 2-5 on treatment, more than 5 days on drug use to the end of treatment, wash-out period and more than 5 days after treatment to the end of the observation period

Baseline characteristics of remdesivir users who had incident ALI or AKI during the observation period were described in this SCCS study. The association between remdesivir use and ALI or AKI during different risk periods were estimated by comparing the rates of event occurrence. Incidence rates, in terms of events per 10,000 person-days, of ALI and AKI over the remdesivir treatment period were calculated. Incidence rate ratios (IRRs) and their corresponding 95% confidence intervals (CIs) of events for different risk periods compared with the baseline period were estimated using a conditional Poisson regression model with an offset for the length of the risk period. Age is not adjusted for in the analysis given the short hospitalisation period of each COVID-19 patient.

To test the credibility and robustness of the main results, sensitivity analyses were conducted to compare the IRRs between different risk periods of (i) removing patients who died during hospitalisation, as death cases within hospitalisation could raise an issue where the exposure that might have otherwise occurred after the event would never be known 37 ; (ii) patients with at least 5 days use of remdesivir; (iii) extending the observation period to 30 April 2021 for discharged cases;

(iv) removing those with events at the day of remdesivir initiation;

(v) removing those re-initiating remdesivir after discontinuation; and To determine the effects in different scenarios, eight subgroup analyses were also performed in this study. Patients were allocated into the following subgroups: (i) age ≤60 years; (ii) age >60 years;

(iii) those who presented with WHO Clinical Progression Scale score ≤4 on remdesivir initiation; (iv) those who presented with WHO Clinical Progression Scale score ≥5 on remdesivir initiation;

(v) those who had remdesivir discontinued; (vi) those who had interferonβ-1b; (vii) those who had ribavirin; and (vii) those who had dexamethasone.

All statistical analyses were performed with the stata version SE 17.0 (StataCorp LLC) and R, and the R code was adapted in an SCCS approach in this study. 40 A two-sided significance level of 5% was used in all statistical analyses. Approximately 7% of the remdesivir recipients developed AKI, which was the most common adverse event for drug discontinuation, 41 but this incidence rate was not significant. Meanwhile, no severe nephrotoxicity was found in a retrospective review of 5-day remdesivir treatment with 15 days follow-up period, but 10.5% of the patients still showed at least 10 ml/min/1.73m 2 decrease in eGFR, which was comparable to data reported in the randomised controlled trial. 15 Similarly, remdesivir did not lead to significant AKI risk at the end of treatment or 2 days after treatment completion even in patients with impaired eGFR of less than 30 ml/min/1.73m 2.42 These results were consistent with our finding that remdesivir initiation was not associated with an increased risk of AKI when compared to pre-exposure period. Meanwhile, based on the pharmacokinetics of remdesivir and its short administration duration, remdesivir was considered safe for patients with impaired renal function, and the benefits of its use may outweigh the risk. 9 Remdesivir was also generally tolerated in kidney transplant patients as AKI was reported in 27% of them where half of them have been diagnosed AKI before administration, at which the peak of serum creatinine was detected, and they retained baseline function 3 days after initiation towards at the end of treatment. 43 Therefore, remdesivir was not responsible for the injury, although randomised controlled trials were necessary to compare the incidence of AKI, especially under the challenge presented by the similar renal complications of COVID-19

and remdesivir. 43 This study was also consistent with our finding of insignificant risk of AKI after remdesivir initiation compared to preexposure. A similar finding was reported in solid-organ transplant recipients whose elevation in GFR or hepatic enzyme was insignificant compared with other antiviral drugs. 44 hospitalisation.

Meanwhile, 25% and 33% of patients had elevated AST and ALT level, respectively; patients generally suffered from different degrees of elevation in liver enzymes, but only a maximum of 6% of the population would have grade 3 elevation or above. 15 A similar finding was reported when comparing remdesivir with other treatments of COVID-19: serum AST and ALT levels were significantly higher in the remdesivir group and the risk of hepatic impairment increased. 46, 47 Some case studies suggested causality of hepatotoxicity as AST and ALT levels were elevated or peaked immediately after the initiation of remdesivir, but the situation ameliorated afterwards. 22, 48, 49 In addition, the disproportionately high reporting of aminotransferase elevation compared with other COVID-19 treatment options suggested drug-induced liver injury. 50 Nonetheless, some studies did not associate remdesivir with liver injury as the difference of clinical measurements was insignificant between treatment and placebo groups. 51 Most patients with kidney transplants also showed no significant hepatoxicity with stable liver function throughout the study period, despite its small sample size. 43 

Abbreviations: CI, confidence interval; IRR, incidence rate ratio.

We thank the Hospital Authority for data provision. 

The study protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (Reference No. UW 20-493). Given the extraordinary nature of the COVID-19 pandemic, individual patient informed consent was not required for this retrospective cohort study using anonymized data.

The manuscript's guarantor affirms that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

The data that support the findings of this study were provided by the Hong Kong Hospital Authority. Restrictions apply to the availability of these data, which were used under license for this study.

Nowcasting epidemics of novel pathogens: lessons from COVID-19

Remdesivir in Covid-19

COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

Pathophysiology of COVID-19-associated acute kidney injury

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

COVID-19 and liver disease: mechanistic and clinical perspectives

SARS-CoV-2 virus and liver expression of host receptors: putative mechanisms of liver involvement in COVID-19

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Remdesivir in patients with acute or chronic kidney disease and COVID-19

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

LiverTox: clinical and research information on druginduced liver injury

Renal and liver injury following the treatment of COVID-19 by remdesivir

Drug-induced liver disturbance during the treatment of COVID-19

Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database

Liver and kidney function in patients with Covid-19 treated with remdesivir

Package leaflet: Information for the patient 2021

Remdesivir: a beacon of hope from Ebola virus disease to COVID-19

Safety profile of the antiviral drug remdesivir: an update

Acetylcysteine for the treatment of suspected Remdesivir-associated acute liver failure in COVID-19: a case series

Early remdesivir to prevent progression to severe Covid-19 in outpatients

Liver injury in remdesivir-treated COVID-19 patients

Safety of remdesivir in patients with acute kidney injury or CKD

Remdesivir in COVID-19 patients with impaired renal function

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial

Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Association of Risk of suicide attempts with methylphenidate treatment

Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19)

Optimal timing of Remdesivir initiation in hospitalized patients with coronavirus disease 2019 (COVID-19) administered with dexamethasone

Hospital Authority: communication kit -coronavirus disease 2019 (COVID-19) formerly named novel coronavirus (nCoV). Version 7.12

Therapeutic Management of Hospitalized Adults with COVID-19

Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19

Drug-induced liver injury: Asia Pacific Association of Study of liver consensus guidelines

Tutorial in biostatistics: the self-controlled case series method

Self controlled case series methods: an alternative to standard epidemiological study designs

Self-controlled case series studies: a modelling guide with R. Chapman & Hall/CRC biostatistics series

Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct

Tutorial in biostatistics: the self-controlled case series method

Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19

A valid warning or clinical Lore: an evaluation of safety outcomes of Remdesivir in patients with impaired renal function from a multicenter matched cohort

Use and safety of Remdesivir in kidney transplant recipients with COVID-19

Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?

Captisol and GS-704277, but not GS-441524, are credible mediators of Remdesivir's nephrotoxicity

Remdesivir induced liver injury and severe COVID-19 infection

Hepatic disorders with the use of Remdesivir for coronavirus 2019

Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection

Abnormal liver biochemistry tests and acute liver injury in COVID-19 patients: current evidence and potential pathogenesis

Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 Using real-world data

S1027 hepatotoxicity of Remdesivir for COVID-19: systematic review and meta-analysis

Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia

Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient

Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19

Management of COVID-19 patients with chronic liver diseases and liver transplants

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial